Overview

Obinutuzumab in Primary FSGS

Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Genentech, Inc.
Treatments:
Obinutuzumab